open access

Vol 23, No 3 (2017)
Original papers
Published online: 2017-09-28
Get Citation

Results of endovascular treatment of iliac and femoral symptomatic lesions. Identification of re-intervention risk factors

Wojciech Stecko, Wojciech Rogala, Marcin Feldo, Marek Ilzecki, Waclaw Karakula, Aleksander Kasprzak, Tomasz Zubilewicz
DOI: 10.5603/AA.2017.0010
·
Acta Angiologica 2017;23(3):115-123.

open access

Vol 23, No 3 (2017)
Original papers
Published online: 2017-09-28

Abstract

Introduction. The aim of the study was to assess a presence of peripheral arterial disease risk factors in patients with symptomatic femoral and iliac lesions treated with use of Jaguar and Supera nitinol stents and to estimate potential relation between these factors and reintervention rate.

Material and methods. The study group consisted of 60 patients between 46 and 85 years of age who presented with typical symptoms of intermittent claudication or critical limb ischemia and underwent percuta­neous transluminal angioplasty with stenting. We examined and divided group into two subgroups — patients who experienced or did not experience need of reintervention in treated lesion.

Results. During the follow-up 24 (40%) of patients underwent reintervention in treated artery due to re­current symptoms of disease. Need of target lesion revascularization occurred more frequent in patients with hypertension (OR = 2.5), patient older than 68 (OR = 1.75) and smokers (OR = 1.75). Patency of all three arteries below knee protected from reintervention.

Conclusions. Jaguar and Supera self-expanding nitinol stents has several advantages and its use were char­acterized by high procedural success and moderate frequency of reintervention correlated to some clinical findings like hypertension. Further studies are necessary to estimate factors disturbing and interfering with long-term patency.

Abstract

Introduction. The aim of the study was to assess a presence of peripheral arterial disease risk factors in patients with symptomatic femoral and iliac lesions treated with use of Jaguar and Supera nitinol stents and to estimate potential relation between these factors and reintervention rate.

Material and methods. The study group consisted of 60 patients between 46 and 85 years of age who presented with typical symptoms of intermittent claudication or critical limb ischemia and underwent percuta­neous transluminal angioplasty with stenting. We examined and divided group into two subgroups — patients who experienced or did not experience need of reintervention in treated lesion.

Results. During the follow-up 24 (40%) of patients underwent reintervention in treated artery due to re­current symptoms of disease. Need of target lesion revascularization occurred more frequent in patients with hypertension (OR = 2.5), patient older than 68 (OR = 1.75) and smokers (OR = 1.75). Patency of all three arteries below knee protected from reintervention.

Conclusions. Jaguar and Supera self-expanding nitinol stents has several advantages and its use were char­acterized by high procedural success and moderate frequency of reintervention correlated to some clinical findings like hypertension. Further studies are necessary to estimate factors disturbing and interfering with long-term patency.

Get Citation

Keywords

self-expanding nitinol stents, risk factors, revascularization

About this article
Title

Results of endovascular treatment of iliac and femoral symptomatic lesions. Identification of re-intervention risk factors

Journal

Acta Angiologica

Issue

Vol 23, No 3 (2017)

Pages

115-123

Published online

2017-09-28

DOI

10.5603/AA.2017.0010

Bibliographic record

Acta Angiologica 2017;23(3):115-123.

Keywords

self-expanding nitinol stents
risk factors
revascularization

Authors

Wojciech Stecko
Wojciech Rogala
Marcin Feldo
Marek Ilzecki
Waclaw Karakula
Aleksander Kasprzak
Tomasz Zubilewicz

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl